MD Anderson Researchers Develop Neo-Bioscore, a More Refined Breast Cancer Staging System

MD Anderson Researchers Develop Neo-Bioscore, a More Refined Breast Cancer Staging System
Researchers at the University of Texas MD Anderson Cancer Center have developed a novel breast cancer staging system called Neo-Bioscore which includes HER2 status of the tumor. This approach is built on increasing evidence that tumor biology knowledge is essential for a more accurate prediction of clinical outcomes, prognosis stratification and better therapeutic planning. The research paper, “The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment,” was published in JAMA Oncology. Stage stratification of breast cancer has historically relied on morphology observations such as size of the primary tumor, metastasis, and presence of disease in the lymph nodes. However, recent research has shown that the biology of individual tumors is extremely important in the choice of treatment, the patient’s response to the chosen therapy, and overall survival outcomes. The new system builds on a previous staging breast cancer system developed and validated by MD Anderson researchers, the CPS+EG, which incorporates the preclinical stage, estrogen receptor status, grade, and post-treatment pathologic stage. Researchers wanted to update the CPS+EG staging system by incorporating HER2 tumor status, as the CPS+EG system predated the routine use of trastuzumab (Herceptin), a drug approved for use as a single or conjugation therapy for the treatment of HER2-positive breast cancer. HER-2 (human epidermal growth factor receptor 2is a cell-surface protein
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.